3M CO（MMM）の決算・業績分析
3M COの2025年有価証券報告書をAI分析。売上高$24.9B(+1.5%)。営業利益$4.6B。Health Care。
目次
3M COの2025年度 業績サマリー
3M CO（証券コード: MMM）の2025年度決算・業績分析。売上高は$24.9B（前年比+1.5%）。営業利益は$4.6B（前年比-4.0%）。純利益は$3.2B（前年比-22.1%）。有価証券報告書を基に、業績変化の要因・リスク・見通し・セグメント構成を AI が分析しました。
3M COの2024年度 注目ポイント
※ 直近の2025年度XBRLデータは取込済みですが、AI分析は2024年度の10-Kを対象としています。
- Revenue declined 26.0% YoY to $26.2B (XBRL), with operating income falling 40.7% to $4.4B (XBRL).
- Despite a 2.4% YoY decline in net income to $5.8B (XBRL), ROE reached 120.2% (XBRL) due to low equity levels.
- Debt-to-equity ratio rose to 9.51x (XBRL), reflecting significant long-term debt of $13.1B (XBRL).
- Free cash flow of $3.8B (XBRL) supported $3.4B in dividends and $1.5B in share repurchases (XBRL).
- Five-year revenue CAGR of -5.6% (XBRL) highlights persistent long-term decline.
3M COの売上高変化の要因
- •Revenue fell 26.0% YoY to $26.2B (XBRL), with historical data showing a decline from $35.4B in FY2023 to $26.2B in FY2024. Segment-specific revenue data is not available in the provided XBRL or 10-K text (XBRL). The five-year CAGR of -5.6% (XBRL) indicates sustained revenue contraction. No specific growth drivers or product performance details are disclosed in the data (XBRL).
3M COの営業利益変化の要因
- •Operating margin remained stable at 16.7% (XBRL), but operating income fell 40.7% YoY to $4.4B (XBRL). Net margin decreased slightly to 22.1% (XBRL), with net income declining 2.4% YoY to $5.8B (XBRL). EBITDA increased 23.7% YoY to $6.2B (XBRL), though gross profit data is not available (XBRL).
3M COの事業リスクと対応
Global economic and geopolitical risks (10-K): 56% of revenue is international, exposing the company to trade tensions, currency fluctuations, and economic downturns.
Foreign currency exchange rate volatility (10-K): U.S. dollar strength could hurt sales and earnings growth.
PFAS-related liabilities (10-K): Regulatory actions on fluorochemicals may increase compliance costs or legal exposure.
Climate change and natural disasters (10-K): Could disrupt supply chains, increase costs, or reduce demand.
Legal/regulatory risks (10-K): Ongoing scrutiny of PFAS compounds may lead to fines, restrictions, or reputational damage.
3M COの事業内容
3M CO (MMM) is a diversified technology company operating in three segments: Safety and Industrial, Transportation and Electronics, and Consumer (10-K). The company generates revenue through the sale of innovative products across industrial, transportation, and consumer markets, leveraging expertise in product development and manufacturing (10-K). Key products include 3M™ Cubitron™ abrasives, Scotch-Brite™ products, and Filtrete™ air filters (10-K). Competitive advantages include innovation and technology integration, though specific intellectual property or barriers to entry are not detailed in the provided data (XBRL).
3M COのAI業績分析レポート（2024年度）
3M CO (MMM) FY2024 Annual Report Analysis
Highlights
Business Overview
3M CO (MMM) is a diversified technology company operating in three segments: Safety and Industrial, Transportation and Electronics, and Consumer (10-K). The company generates revenue through the sale of innovative products across industrial, transportation, and consumer markets, leveraging expertise in product development and manufacturing (10-K). Key products include 3M™ Cubitron™ abrasives, Scotch-Brite™ products, and Filtrete™ air filters (10-K). Competitive advantages include innovation and technology integration, though specific intellectual property or barriers to entry are not detailed in the provided data (XBRL).
Revenue Analysis
Revenue fell 26.0% YoY to $26.2B (XBRL), with historical data showing a decline from $35.4B in FY2023 to $26.2B in FY2024. Segment-specific revenue data is not available in the provided XBRL or 10-K text (XBRL). The five-year CAGR of -5.6% (XBRL) indicates sustained revenue contraction. No specific growth drivers or product performance details are disclosed in the data (XBRL).
Profitability Analysis
Operating margin remained stable at 16.7% (XBRL), but operating income fell 40.7% YoY to $4.4B (XBRL). Net margin decreased slightly to 22.1% (XBRL), with net income declining 2.4% YoY to $5.8B (XBRL). EBITDA increased 23.7% YoY to $6.2B (XBRL), though gross profit data is not available (XBRL).
Balance Sheet Analysis
Equity ratio declined to 9.5% (XBRL), with total equity dropping from $15.0B in FY2022 to $4.8B in FY2024 (XBRL). Long-term debt rose to $13.1B (XBRL), resulting in a debt-to-equity ratio of 9.51x (XBRL). Current ratio of 1.07x (XBRL) indicates tight liquidity, with total assets increasing to $50.6B (XBRL) in FY2024.
Cash Flow Analysis
Operating cash flow of $5.6B (XBRL) supported $3.8B in free cash flow (FCF) after $1.7B in capital expenditures (CapEx) (XBRL). Financing cash flow was negative $5.3B (XBRL), driven by $3.4B in dividends paid and $1.5B in share repurchases (XBRL). Investing cash flow was negative $1.0B (XBRL).
Working Capital Analysis
Cash conversion cycle (CCC) was 77 days (XBRL), with receivables days at 50 days, inventory days at 91 days, and payables days at 64 days (XBRL).
Risks
Outlook
N/A (XBRL). No specific management guidance or forward-looking trends are disclosed in the provided data (XBRL).
Historical Time Series
| Metric | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | 32.8B | 32.1B | 32.2B | 35.4B | 26.2B | 24.6B |
| Operating Income | 7.2B | 6.2B | 7.2B | 7.4B | 4.4B | -10.7B |
| Net Income | 5.3B | 4.5B | 5.4B | 5.9B | 5.8B | -7.0B |
| Total Assets | 44.7B | 47.3B | 47.1B | 46.5B | 50.6B | 39.9B |
| Total Equity | 10.1B | 12.9B | 15.0B | 14.7B | 4.8B | 3.8B |
| Operating Cash Flow | 6.4B | 7.1B | 8.1B | 7.5B | 5.6B | 6.7B |
Health Careの企業一覧
3M COと同じ「Health Care」セクターの企業